US Measles Cases Hit 4,852 in 2026, the Worst Year Since 1991 — and 6,500 Is Now the Line to Watch

On 30 October, the US Centers for Disease Control and Prevention reported 4,852 confirmed measles cases in the United States as of 29 October, up 264 from the previous weekly update. That is already more than double the 2,289 cases recorded in all of 2025, and the highest single-year total since 1991, when the country reported 9,643 cases. Measles was declared eliminated in the United States in 2000, which meant no continuous domestic transmission for at least twelve months. This year has broken that story in the plainest way a number can: the disease is not just back, it is spreading in clusters across 47 jurisdictions.

The shape of the outbreak matters as much as the total. Ninety-six percent of cases are outbreak-associated, with 43 new outbreaks designated in 2026, and 96% of patients were unvaccinated or of unknown vaccination status, up from 93% in 2025. Hospitalizations stand at 511, about 11% of all cases. Children aged 5 to 19 account for 2,010 cases, adults 20 and older for 1,996, and children under 5 for 812. Pennsylvania alone has reported 1,426 cases and 268 hospitalizations as of 30 October, nearly three in ten cases nationwide, which means the national curve is, to a large extent, the curve of a few large clusters. That concentration cuts both ways: a single outbreak ending can bend the national total down, and a single outbreak flaring can push it up.

There is also a verdict hanging over the numbers that has nothing to do with counting. The Pan American Health Organization postponed its review of the United States' measles elimination status from April to November 2026, and a determination is now expected. Losing that status would not change any patient's treatment, but it would be a formal acknowledgment that sustained domestic transmission has returned, and it would sit oddly beside the fact that the country once eliminated a disease it now cannot contain. The review is the institutional version of the question the case count already asks: how did a preventable disease become a national outbreak again, and what, if anything, stops it from getting worse?

That is where the prediction market comes in, and it is unusually readable. On Polymarket, the market asking whether there will be at least 6,500 measles cases in the United States in 2026, resolved on the CDC's own case counter, traded at 67.5% for Yes on 2 November, with about $65,900 changing hands in the previous 24 hours; the companion market for at least 6,000 cases traded at 87%. The arithmetic behind the 6,500 line is simple. From 4,852 on 29 October, the country needs 1,648 more cases in the nine weeks left in the year, an average of about 183 a week. The last two weekly increases were 178 and then 264, averaging about 221. If that pace simply held, the year would end near 6,840, above the line. Yet expert projections reported in October put the year-end total at 6,000 to 6,500, a range whose top edge is exactly the market's line. The gap between the recent pace and those projections is the whole argument: outbreak counts are lumpy, driven by clusters like Pennsylvania's, and a pace set by two weeks is not a trend.

My own judgment sits slightly below the market, at 60%. The recent pace clears the required weekly rate, and two months of remaining transmission is a long time for a disease this contagious, but I am not willing to go higher when the expert range straddles the threshold and the national total depends so heavily on whether one or two large outbreaks keep growing. If weekly additions stay above roughly 185 through November, the case for Yes strengthens fast; if they fall back below that pace as the largest clusters peak, 6,500 slips away. Either way, the number to watch is not just the total but the weekly increment, because that is where this outbreak will be won or lost, one cluster at a time.